Research & Development
Access to Healthcare
Who We Are
Share Data & Analysis
Working at Novartis
Awards & Recognition
Compensation & Benefits
Careers in Research
New five-year data support superiority of Novartis drug Tasigna® over
® in newly diagnosed Ph+ CML patients
... in newly diagnosed Ph+ CML patients on Tasigna versus
 Data demonstrated higher rates of early and deeper ... in patients who switch after long-term treatment with
 New data show patients who failed to respond to frontline ...
Six-year pivotal study data reinforce the superiority of Tasigna® over
® in newly-diagnosed patients with Ph+ CML
Fewer patients on Tasigna vs.
had their leukemia progress to advanced stage, a key goal of treatment ... confirm the favorable risk/benefit profile of Tasigna vs.
in newly-diagnosed CML patients Basel, December 8, 2014 - ... the superiority of Tasigna ® (nilotinib) compared to
® (imatinib)[*] at achieving higher rates of early, deep and ...
Patents and Medical Progress
... patents to development of medicines; information about the
patent case in India. To continue to provide patients with safe and ...
Oncology Patient Assistance Programs
... largest oncology patient access program at Novartis – the
International Patient Assistance Program (GIPAP) is the first global ... about GIPAP from The Max Foundation Learn about the
patent case in India Oncology Patient Assistance ...
... (USD) Business franchise
.jpg 4,746 1% Oncology ...
Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS
... deep molecular response with Tasigna ® versus
® in Ph+ CML patients Overall survival data from ... responses with Tasigna ® (nilotinib) compared with
® (imatinib)[*] therapy in a variety of appropriate Philadelphia ...
Reducing Our Product Footprint
... Exforge Galvus Gilenya
/Gleevec Lucentis Rasilez/Tekturna Rasilez-HCT ...
Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML
... MR4.0 rate in all treated patients with <=3 months of prior
treatment (n=1,052) was 38.4% at 18 months and 40.4% at 24 months. As ... MR4.5, and a reduced risk of progression compared to
. Consistent with prior studies, ENEST1st demonstrated the importance ...
Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014
... are reminded of how far we've come since the unprecedented
data unveiled exactly 15 years ago - a turning point in precision ... , www.afinitor.com , www.tasigna.com , www.
.com and www.exjade.com . Because CTL019, BKM120, LGH447, ...
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
... , www.jakavi.com , www.tasigna.com , www.
.com , www.afinitor.com and www.exjade.com . Because LBH589, ... new indications or labeling for Zykadia, Jakavi, Tasigna,
, Afinitor or Exjade, potential marketing approvals for LBH589, LDE225, ...
© 2015 Novartis AG
This site is intended for a global audience.